Treatment of hypermenorrhea with mefenamic acid in women using IUDs.
49 women using either Lippes Loop D or copper T220C IUDs who were complaining of increased menstrual bleeding, were treated with mefenamic acid at a dosage of 500 mg 3 times/day for 5 days during their menstrual periods.  Menstrual bleeding of each patient was quantified before initiation of the treatment and figures so obtained were used as pretreatment control values; during their 2nd cycle they received 1 placebo tablet 3 times/day for 5 days, the next 2 cycles utilized treatment with mefenamic acid, followed by a 5th cycle on placebo, and a 6th one without treatment.  Of the 49 women admitted to the trial, 20 had pretreatment menstrual bleeding of more than 80 ml and 29 had less than 80 ml; groups 1 and 2, respectively.  For group 1, a significant decrease in menstrual bleeding of 49.5% and 37.4% was observed during the 2 treatment cycles.  Group 2, subjects with menstrual bleeding within the normal range, showed no decrease in menstrual bleeding.
D001695:Biology; D003267:Contraception; D004194:Disease; D004703:Endocrine System; D005193:Family Planning Services; D006454:Hemoglobins; D006470:Hemorrhage; D007434:Intrauterine Devices; D007435:Intrauterine Devices, Copper; D008599:Menstruation Disturbances; D010827:Physiology; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D012816:Signs and Symptoms; D013812:Therapeutics
D006454:Hemoglobins; D011448:Prostaglandin Antagonists; D011453:Prostaglandins
Biology; Bleeding; Contraception; Contraceptive Methods--side effects; Diseases; Endocrine System; Family Planning; Hemoglobin Level; Iud, Copper Releasing; Iud, Unmedicated; Iud--side effects; Menstruation Disorders; Physiology; Prostaglandin Antagonists; Prostaglandins; Signs And Symptoms; Treatment